Teva Pharmaceutical (NASDAQ:TEVA) closed Friday's positive trading session at $50.46. In the past year, the stock has hit a 52-week low of $46.99 and 52-week high of $64.95. Teva Pharmaceutical stock has been showing support around $49.88 and resistance in the $50.92 range. Technical indicators for the stock are Bearish and S&P gives TEVA a positive 4 STARS (out of 5) buy rating. For a hedged play on this stock, look at the Jun '11 $52.50 covered call for a net debit in the $48.80 area. That is also the break-even stock price for this trade. This covered call has a duration of 110 days, provides 3.29% downside protection and an assigned return rate of 7.58% for an annualized return rate of 25.16% (for comparison purposes only). A lower-cost hedged play for this stock would use a longer term call option in place of the covered call stock purchase. To use this strategy look at going long the TEVA Jan '12 $37.50 call and selling the Jun '11 $52.50 call for a total debit of $11.94. The trade has a lifespan of 110 days and would provide 2.02% downside protection and an assigned return rate of 25.63% for an annualized return rate of 85% (for comparison purposes only). Teva Pharmaceutical has a current annual dividend yield of 1.70%.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac...
-
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma...
-
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th...
-
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y...
-
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after...
-
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ...
-
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment